Trial Profile
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 16 Feb 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Jul 2024.
- 16 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2024.